Patent US4330530A successfully refreshed from Google Patents.
US4330530A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-arthritic compositions and method using gold salts and organophosphonates
Assignee: Procter and Gamble Co
•
Filing: 1980-12-22
•
Granted: 1982-05-18
•
Expires: 2000-12-22
Abstract
Abstract Compositions comprising pharmaceutically-acceptable gold salts and organophosphonates, especially the geminal diphosphonates, useful in the treatment of arthritic conditions, are disclosed. The method of treating arthritic conditions using these compositions is also disclosed.
Inventors
- 👤 Bennie L. Baker
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 12:57
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K33/00; A61K33/24; A61K33/242
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
194 words
A method for treating arthritic conditions comprising administering to a human or animal in need of such treatment a safe and effective amount, not less than about 200 mg. per day, of an organophosphonate compound and a safe and effective amount, within the range from about 5 to about 200 mg. per week, of a pharmaceutically-acceptable gold salt useful in the treatment of such conditions, wherein the organophosphonate compound is selected from the group consisting of ##STR3## wherein R 3 is hydrogen, alkyl containing from 1 to about 20 carbon atoms, alkenyl containing from 2 to about 20 carbon atoms, aryl, phenylethenyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH), or --CH 2 CH(PO 3 H 2 ) 2 ; R 4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 , and the pharmaceutically-acceptable salts thereof, and wherein the gold salt is selected from the group consisting of gold sodium thiomalate, gold sodium thiosulfate, triethylphosphine gold, gold sodium thioglucose and mixtures thereof.
Claim 2
Independent Claim
194 words
A method for treating arthritic conditions comprising administering to a human or animal in need of such treatment a safe and effective amount, not less than about 200 mg. per day, of an organophosphonate compound and a safe and effective amount, within the range from about 5 to about 200 mg. per week, of a pharmaceutically-acceptable gold salt useful in the treatment of such conditions, wherein the organophosphonate compound is selected from the group consisting of ##STR3## wherein R 3 is hydrogen, alkyl containing from 1 to about 20 carbon atoms, alkenyl containing from 2 to about 20 carbon atoms, aryl, phenylethenyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH), or --CH 2 CH(PO 3 H 2 ) 2 ; R 4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 , and the pharmaceutically-acceptable salts thereof, and wherein the gold salt is selected from the group consisting of gold sodium thiomalate, gold sodium thiosulfate, triethylphosphine gold, gold sodium thioglucose and mixtures thereof.
Claim 3
Dependent Claim
31 words
A method according to claim 1 wherein the organophosphonate compound is selected from the group consisting of dichloromethanediphosphonic acid, ethane-1-hydroxy-1,1-diphosphonic acid, methanediphosphonic acid, pharmaceutically-acceptable salts of these acids, and mixtures thereof.
Claim 4
Dependent Claim
151 words
A pharmaceutical composition in unit dosage form comprising from about 50 mg. to about 500 mg. of an organophosphonate compound selected from the group consisting of ##STR4## wherein R 3 is hydrogen, alkyl containing from 1 to about 20 carbon atoms, alkenyl containing from 2 to about 20 carbon atoms, aryl, phenylethenyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH), or --CH 2 CH(PO 3 H 2 ) 2 ; R 4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 , and the pharmaceutically-acceptable salts thereof, and from about 1 mg. to about 200 mg. of a gold salt selected from the group consisting of gold sodium thiomalate, gold sodium thiosulfate, triethylphosphine gold, gold sodium thioglucose, and mixtures thereof.
Claim 5
Dependent Claim
151 words
A pharmaceutical composition in unit dosage form comprising from about 50 mg. to about 500 mg. of an organophosphonate compound selected from the group consisting of ##STR4## wherein R 3 is hydrogen, alkyl containing from 1 to about 20 carbon atoms, alkenyl containing from 2 to about 20 carbon atoms, aryl, phenylethenyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH), or --CH 2 CH(PO 3 H 2 ) 2 ; R 4 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 , and the pharmaceutically-acceptable salts thereof, and from about 1 mg. to about 200 mg. of a gold salt selected from the group consisting of gold sodium thiomalate, gold sodium thiosulfate, triethylphosphine gold, gold sodium thioglucose, and mixtures thereof.
Claim 6
Dependent Claim
30 words
A composition according to claim 3 wherein the organophosphonate compound is selected from the group consisting of dichloromethanediphosphonic acid, ethane-1-hydroxy-1,1-diphosphonic acid, methanediphosphonic acid, and the pharmaceutically-acceptable salts of these acids.
References Cited (Backward Citations)
US3553314A
Cited
US3584125A
Cited
US3553315A
Cited
US3584124A
Cited
US3678164A
Cited
US3641246A
Cited
US3662066A
Cited
US3683080A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-05-17 | 1985-11-16 | 1986-05-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-05-17 | 1989-11-16 | 1990-05-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-05-17 | 1993-11-16 | 1994-05-18 | $7700.00 | Window Closed / Lapsed |